Nyanbol Kuol, Xu Yan, Jimsheena Karakkat, Stamatis Vassilaros, Ioannis Fyssas, Anastasios Tsibanis, Sarah Fraser, Kulmira Nurgali, Vasso Apostolopoulos
{"title":"<i>Interferon Gamma</i> Gene Polymorphisms in Greek Primary Breast Cancer Patients.","authors":"Nyanbol Kuol, Xu Yan, Jimsheena Karakkat, Stamatis Vassilaros, Ioannis Fyssas, Anastasios Tsibanis, Sarah Fraser, Kulmira Nurgali, Vasso Apostolopoulos","doi":"10.31083/j.fbs1604025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a heterogeneous disease with distinct clinical subtypes, categorized by hormone receptor status, which exhibits different prognoses and requires personalized treatment approaches. These subtypes included luminal A and luminal B, which have different prognoses. Breast cancer development and progression involve many factors, including interferon-gamma (<i>IFNG</i>). Moreover, single nucleotide polymorphisms (SNPs) in <i>IFNG</i> have been associated with cancer risk. However, the functional role of <i>IFNG</i> polymorphisms in primary breast cancer subtypes, luminal A and luminal B, is unclear.</p><p><strong>Methods: </strong>A total of 138 breast cancer tissues were acquired: 81 had luminal A, 42 had luminal B, 10 had triple-negative, and 3 had human epidermal growth factor receptor 2 (HER2) subtypes, while 2 had missing data. The tissues were evaluated in relation to luminal A and luminal B primary breast cancer subtypes. DNA was extracted from freshly frozen samples, and three SNPs (rs1861493 (chr12:68157416 (GRCh38.p13)), rs1861494 (chr12:68157629 (GRCh38.p13)) and rs2430561 (chr12:68158742 (GRCh38.p13))) in the <i>IFNG</i> gene were selected and evaluated based on previously published associations with cancer or other diseases.</p><p><strong>Results: </strong>The data showed that <i>IFNG</i> polymorphisms rs1861493 and rs1861494 were associated with breast cancer risk, with the A allele of rs1861493 and T allele of rs1861494 being noted as the risk alleles. Furthermore, the <i>IFNG</i> polymorphism rs2430561 was associated with breast cancer risk, with the A allele being the risk allele. In addition, the risk alleles were more prevalent in the more aggressive subtype, luminal B breast cancer, compared to luminal A. Similarly, the rs2430561 AA genotype was associated with the breast cancer severity.</p><p><strong>Conclusion: </strong><i>IFNG</i> polymorphisms rs1861493, rs1861494, and rs2430561, with their respective risk alleles, are associated with increased breast cancer risk and severity. These risk alleles are more prevalent in the aggressive luminal B subtype compared to luminal A, indicating their role in both the prevalence and prognosis of breast cancer in a Greek population.</p>","PeriodicalId":73070,"journal":{"name":"Frontiers in bioscience (Scholar edition)","volume":"16 4","pages":"25"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Scholar edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/j.fbs1604025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer is a heterogeneous disease with distinct clinical subtypes, categorized by hormone receptor status, which exhibits different prognoses and requires personalized treatment approaches. These subtypes included luminal A and luminal B, which have different prognoses. Breast cancer development and progression involve many factors, including interferon-gamma (IFNG). Moreover, single nucleotide polymorphisms (SNPs) in IFNG have been associated with cancer risk. However, the functional role of IFNG polymorphisms in primary breast cancer subtypes, luminal A and luminal B, is unclear.
Methods: A total of 138 breast cancer tissues were acquired: 81 had luminal A, 42 had luminal B, 10 had triple-negative, and 3 had human epidermal growth factor receptor 2 (HER2) subtypes, while 2 had missing data. The tissues were evaluated in relation to luminal A and luminal B primary breast cancer subtypes. DNA was extracted from freshly frozen samples, and three SNPs (rs1861493 (chr12:68157416 (GRCh38.p13)), rs1861494 (chr12:68157629 (GRCh38.p13)) and rs2430561 (chr12:68158742 (GRCh38.p13))) in the IFNG gene were selected and evaluated based on previously published associations with cancer or other diseases.
Results: The data showed that IFNG polymorphisms rs1861493 and rs1861494 were associated with breast cancer risk, with the A allele of rs1861493 and T allele of rs1861494 being noted as the risk alleles. Furthermore, the IFNG polymorphism rs2430561 was associated with breast cancer risk, with the A allele being the risk allele. In addition, the risk alleles were more prevalent in the more aggressive subtype, luminal B breast cancer, compared to luminal A. Similarly, the rs2430561 AA genotype was associated with the breast cancer severity.
Conclusion: IFNG polymorphisms rs1861493, rs1861494, and rs2430561, with their respective risk alleles, are associated with increased breast cancer risk and severity. These risk alleles are more prevalent in the aggressive luminal B subtype compared to luminal A, indicating their role in both the prevalence and prognosis of breast cancer in a Greek population.
背景:乳腺癌是一种异质性疾病,有不同的临床亚型,按激素受体状态分类,表现出不同的预后,需要个性化的治疗方法。这些亚型包括管腔 A 型和管腔 B 型,它们的预后不同。乳腺癌的发生和发展涉及多种因素,包括γ干扰素(IFNG)。此外,IFNG 中的单核苷酸多态性(SNPs)也与癌症风险有关。然而,IFNG多态性在原发性乳腺癌亚型(管腔A型和管腔B型)中的功能作用尚不清楚:方法:共采集了 138 例乳腺癌组织:方法:共采集了 138 例乳腺癌组织:81 例为管腔 A 型,42 例为管腔 B 型,10 例为三阴性,3 例为人类表皮生长因子受体 2(HER2)亚型,2 例数据缺失。根据管腔 A 型和管腔 B 型原发性乳腺癌亚型对组织进行了评估。从新鲜冷冻样本中提取DNA,并根据之前发表的与癌症或其他疾病的相关性,选择并评估了IFNG基因中的3个SNPs(rs1861493 (chrr12:68157416 (GRCh38.p13))、rs1861494 (chrr12:68157629 (GRCh38.p13))和rs2430561 (chrr12:68158742 (GRCh38.p13)):数据显示,IFNG多态性rs1861493和rs1861494与乳腺癌风险有关,其中rs1861493的A等位基因和rs1861494的T等位基因被认为是风险等位基因。此外,IFNG 多态性 rs2430561 与乳腺癌风险有关,其中 A 等位基因是风险等位基因。同样,rs2430561的AA基因型也与乳腺癌的严重程度有关:结论:IFNG 多态性 rs1861493、rs1861494 和 rs2430561 及其各自的风险等位基因与乳腺癌风险和严重程度的增加有关。与管腔 A 亚型相比,这些风险等位基因在侵袭性管腔 B 亚型中更为普遍,这表明它们在希腊人群中乳腺癌的患病率和预后中都扮演着重要角色。